Replimune Group, Inc. (REPL): Price and Financial Metrics

Replimune Group, Inc. (REPL): $9.46

0.64 (+7.26%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

REPL Price/Volume Stats

Current price $9.46 52-week high $24.81
Prev. close $8.82 52-week low $4.92
Day low $9.08 Volume 2,000,900
Day high $9.76 Avg. volume 1,266,414
50-day MA $6.66 Dividend yield N/A
200-day MA $10.05 Market Cap 580.99M

REPL Stock Price Chart Interactive Chart >


Replimune Group, Inc. (REPL) Company Bio


Replimune Ltd. develops oncolytic immunotherapies for the treatment of cancer. It is developing various proprietary products intended to enhance the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. The company was founded in 2015 is based in Abingdon, the United Kingdom.


REPL Latest News Stream


Event/Time News Detail
Loading, please wait...

REPL Latest Social Stream


Loading social stream, please wait...

View Full REPL Social Stream

Latest REPL News From Around the Web

Below are the latest news stories about REPLIMUNE GROUP INC that investors may wish to consider to help them evaluate REPL as an investment opportunity.

Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference

WOBURN, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 11:15 AM PT at the Westin St. Francis Hotel in San Francisco, CA. A simultaneous webcast will be available in the Investors

Yahoo | December 28, 2023

An Intrinsic Calculation For Replimune Group, Inc. (NASDAQ:REPL) Suggests It's 24% Undervalued

Key Insights Using the 2 Stage Free Cash Flow to Equity, Replimune Group fair value estimate is US$9.64 Replimune Group...

Yahoo | December 7, 2023

Why Is Replimune (REPL) Stock Down 48% Today?

Replimune stock is dropping on Tuesday as investors in REPL shares react to a clinical trial missing both of its primary endpoints.

William White on InvestorPlace | December 5, 2023

Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not meet either of the two primary endpoints Positive data update for full 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma reinforces durable benefit; biologics license application (BLA) submission planned for 2H 2024 RP1 monotherapy data from ARTACUS clinical trial a

Yahoo | December 5, 2023

Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research

RP2 as monotherapy and in combination with nivolumab showed a favorable safety profile and durable responses in nearly 30 percent of patients, all with previously treated diseaseWOBURN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated data from a cohort of metastatic uveal melanoma patients enrolled in the open-label, multicent

Yahoo | November 8, 2023

Read More 'REPL' Stories Here

REPL Price Returns

1-mo 38.91%
3-mo 10.90%
6-mo 17.37%
1-year -60.62%
3-year -72.62%
5-year -24.86%
YTD 12.22%
2023 -69.01%
2022 0.37%
2021 -28.96%
2020 165.85%
2019 43.50%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!